Previous 10 | Next 10 |
Gainers : Ra Pharmaceuticals, Inc. (NASDAQ: RARX ) +100% . OncoSec Medical Incorporated (NASDAQ: ONCS ) +34% . ProPetro Holding Corp. (NYSE: PUMP ) +22% . Mereo BioPharma Group plc (NASDAQ: MREO ) +21% . Bed Bath & Beyond (NASDAQ: BBBY ) +20% . Caladrius Biosciences (NASDAQ: CLBS ...
Mereo Biopharma (NASDAQ: MREO ) initiated with Outperform rating and $8 (177% upside) price target at SVB Leerink. More news on: Mereo BioPharma Group plc, The Medicines Company, UnitedHealth Group Incorporated, Healthcare stocks news, Stocks on the move, , Read more ...
Introduction Mereo BioPharma ( MREO ) is a British small-cap ($62M) biopharma developing therapeutics for rare disorders as well as endocrine and oncological diseases. MREO has a diverse pipeline including MPH-966 (alvelestat), BCT-197 (acumapimod), and OMP-305B83 (navicixizumab) for alp...
Pfenex (NYSEMKT: PFNX ) +13% as FDA OKs Pfenex Forteo biosimilar. More news on: Pfenex Inc., Mereo BioPharma Group plc, Livongo Health, Inc., Stocks on the move, Read more ...
Thinly traded nano cap Mereo BioPharma Group (NASDAQ: MREO ) is up 6% premarket on increased volume, albeit on turnover of only 29K shares, in reaction to Fast Track designation in the U.S. for Phase 1-stage bispecific antibody navicixizumab for heavily pretreated patients with...
LONDON and REDWOOD CITY, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or the "Company" or the "Group," a clinical stage biopharmaceutical company focused on rare diseases, today announces that the U.S. Food and Drug Administration (...
Mereo BioPharma Group plc (MREO) 2019 Interim Financial Results and Corporate Update Conference Call September 17, 2019 8:00 AM ET Company Participants Richard Jones – Chief Financial Officer Denise Scots-Knight – Chief Executive Officer Conference Call Participant...
The following slide deck was published by Mereo BioPharma Group plc in conjunction with their 2019 Q2 earnings Read more ...
Mereo BioPharma Group (NASDAQ: MREO ): 1H GAAP EPS of -£0.22. More news on: Mereo BioPharma Group plc, Earnings news and commentary, Healthcare stocks news, , Read more ...
12-Month Topline Results from Phase 2b ASTEROID Study with Setrusumab for Osteogenesis Imperfecta (OI) Expected in Q4 2019; Positive 6-Month Data to be Featured in Late-Breaking Oral Presentation at ASBMR 2019 Conference Call Today at 8:30 a.m. EDT / 1:30 p.m. BST LONDON and REDWOOD C...
News, Short Squeeze, Breakout and More Instantly...
Mereo BioPharma Group Company Name:
MREO Stock Symbol:
NASDAQ Market:
LONDON, April 03, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutica...
LONDON, April 03, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate ...
2024-03-28 08:00:08 ET Gil Blum from Needham issued a price target of $6.00 for MREO on 2024-03-28 07:08:00. The adjusted price target was set to $6.00. At the time of the announcement, MREO was trading at $3. The overall price target consensus is at $4.00 with high pric...